The Power of QTORIN™
Our Platform
QTORIN™ is a patented and versatile platform designed to deliver APIs to deep layers of the skin to locally treat a broad spectrum of rare skin diseases.
The Power of QTORIN™ rapamycin
Palvella’s proprietary QTORIN™ platform was developed over several years of research aimed at overcoming these challenges. The QTORIN™ platform provides targeted delivery to the main area of concern, usually within the deep layers of the epidermis or dermis.
QTORIN™ helps stabilize rapamycin, which is highly susceptible to degradation. Our QTORIN™ rapamycin 3.9% is stable at room temperature in our pump dispenser for extended periods.
QTORIN™ rapamycin 3.9% topical gel is a high-strength formulation that provides local and target therapeutic effect with minimal systemic absorption.
Prior to the QTORIN™ platform, rapamycin exhibited very poor skin absorption due to its high molecular weight and poor stability. QTORIN™ rapamycin 3.9% formulation yields optimal epidermal and dermal distribution with systemic absorption achieving only picogram levels in clinical studies.
The Impact
All of Palvella’s programs, including QTORIN™ rapamycin 3.9%, leverage QTORIN™ to deliver the active cargos directly to the site of genetic pathology of each disease. QTORIN™ could potentially apply to a range of diseases and drugs, including single agents and fixed combinations.
Innovation is here.
Be a part of what’s next and invest in the future of rare skin disease treatment.